SEC 13F Intelligence

Managers / Q1 2022 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$139M
Q1 2022
Positions
63
Filings on Record
39
2019–present window
Filed
May 13, 2022
original filing

Summary

Birchview Capital, LP reported $139M in U.S.-listed holdings across 63 positions for Q1 2022.

The portfolio is heavily concentrated: BMY alone accounts for 39.6% of reported value.

Compared with Q4 2021, the fund opened 1 new position and exited 5.

Portfolio Metrics

Turnover
+9.3%
vs prior filed quarter
Top-10 Concentration
+71.9%
share of reported value
Largest Position
+39.6%
Bristol Myers Squibb
New / Exited
1 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 90.6%Other: 9.4%
  • Common Stock · 90.6% · $126M
  • Other · 9.4% · $13M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PHRPHREESIA INCNEW+10.0K10.0K+$264,000$264,000
DCGODOCGO INCADDED+100.0K110.0K+$924,000$1M
SOLENO THERAPEUTICS INCADDED+2.80M3.68M+$460,000$820,000
ARNAEURARENA PHARMACEUTICALS INCSOLD OUT−22.0K0−$2M$0
PGNYPROGYNY INCSOLD OUT−15.0K0−$755,000$0
TGTXTG THERAPEUTICS INCSOLD OUT−15.0K0−$285,000$0
PFEPFIZER INCSOLD OUT−4.0K0−$236,000$0
TXMDEURTHERAPEUTICSMD INCSOLD OUT−50.0K0−$18,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM39.65%$55M754.1K
2NBIXNEUROCRINE BIOSCIENCES INChistory →COM6.02%$8M89.2K
3ELUTAZIYO BIOLOGICS INChistory →COM5.96%$8M1.42M
4QDEL*QUIDEL CORPhistory →COM4.83%$7M59.7K
5ACADACADIA PHARMACEUTICALS INChistory →COM3.48%$5M199.4K
6FHTXFOGHORN THERAPEUTICS INChistory →COM3.23%$4M294.1K
7BDQMALBIREO PHARMA INChistory →COM2.43%$3M113.0K
8ACCELERATE DIAGNOSTICS INCCOM2.33%$3M2.25M
9UTHUNITED THERAPEUTICS CORPhistory →COM2.32%$3M18.0K
10CLRUSDCONTINENTAL RESOURCES INChistory →COM1.70%$2M38.6K
11BIIBBIOGEN INChistory →COM1.53%$2M10.1K
12BIODESIX INCCOM1.52%$2M1.25M
13KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM1.43%$2M269.3K
14OVVOVINTIV INChistory →COM1.33%$2M34.2K
15BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM1.20%$2M14.0K
16PROTHENA CORP PLCSHS1.11%$2M42.0K
17MASI*MASIMO CORPCOM0.97%$1M9.3K
18ALKERMES PLCSHS0.95%$1M50.0K
19HROWHARROW HEALTH INCCOM0.88%$1M180.0K
20HTDCORCEPT THERAPEUTICS INCCOM0.81%$1M50.0K
21INBXUSDINHIBRX INCCOM0.81%$1M50.4K
22ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.81%$1M133.1K
23GOSSGOSSAMER BIO INCCOM0.81%$1M129.1K
24DCGODOCGO INCCOM0.73%$1M110.0K
25ARVNARVINAS INCCOM0.73%$1M15.0K
26AMARIN CORP PLCSPONS ADR NEW0.71%$987,000300.0K
27PXDEURPIONEER NATURAL RESOURCES COCOM0.68%$950,0003.8K
28CYTKCYTOKINETICS INCCOM0.66%$920,00025.0K
29IMGNEURIMMUNOGEN INCCOM0.65%$904,000190.0K
30PTGXPROTAGONIST THERAPEUTICS INCCOM0.65%$900,00038.0K
31SOLENO THERAPEUTICS INCCOM0.59%$820,0003.68M
32AVEO PHARMACEUTICALS INCCOM0.56%$783,000140.0K
33CFRXEURCONTRAFECT CORPCOM0.53%$730,000200.0K
34INARI MEDICAL INCCOM0.52%$725,0008.0K
35NKTREURNEKTAR THERAPEUTICSCOM0.50%$690,000128.0K
36IRTCIRHYTHM TECHNOLOGIES INCCOM0.45%$630,0004.0K
37APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.44%$610,00012.0K
384XC1KALVISTA PHARMACEUTICALS INCCOM0.42%$590,00040.0K
39TSVT*2SEVENTY BIO INCCOM0.42%$586,00034.3K
40VNDAVANDA PHARMACEUTICALS INCCOM0.41%$566,00050.0K
41CCXIEURCHEMOCENTRYX INCCOM0.36%$501,00020.0K
42CGEMCULLINAN ONCOLOGY INCCOM0.34%$472,00045.1K
43SILKUSDSILK ROAD MEDICAL INCCOM0.30%$413,00010.0K
44BLUEBIRD BIO INCCOM0.29%$407,00084.0K
45ZNTLZENTALIS PHARMACEUTICALS INCCOM0.27%$369,0008.0K
46AM6AMICUS THERAPEUTICS INCCOM0.26%$360,00038.0K
47VTYXUSDVENTYX BIOSCIENCES INCCOM0.24%$339,00025.0K
48XNCRXENCOR INCCOM0.24%$328,00012.3K
49BCRXBIOCRYST PHARMACEUTICALS INCCOM0.23%$325,00020.0K
50STOKSTOKE THERAPEUTICS INCCOM0.23%$316,00015.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.